<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="15" offset="0" totalResults="15"><SearchResults><Trial Id="89315"><Indications><Indication>Allergic conjunctivitis</Indication><Indication>Allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Allergen</Action><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Immunomodulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Peptide</Technology><Technology>Quick release formulation</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><DateChangeLast>2018-11-23T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-001855-38</Identifier><Identifier>8237-003</Identifier><Identifier>NCT01644617</Identifier><Identifier>P07627</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspepsia</Indication><Indication>Edema</Indication><Indication>Pruritus</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Mitizax alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>124</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237 , compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in adult subjects. The hypothesis was that administration of MK-8237 , compared to placebo, results in dose-related improvement in Average Total Nasal Symptom Score (TNSS) during Environmental Exposure Chamber (EEC) Challenge [ 1531369 ], [ 1617604 ]. The randomized</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic conjunctivitis - Assessment of Conjunctivitis Symptoms - Total symptom score(TSS)</EndpointIndex><EndpointIndex>Allergic conjunctivitis - Assessment of Medication Use</EndpointIndex><EndpointIndex>Allergic conjunctivitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulin levels</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Assessment by nasal provocation test( NPT)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Dose-ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic conjunctivitis - Subjects with Chronic Allergic Conjunctivitis</PatientSegment><PatientSegment>Allergic conjunctivitis - Subjects with Perennial Allergic Conjunctivitis(PAC)</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin E </BiomarkerName><BiomarkerName> Immunoglobulin G</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Karl Boegl</Name></ContactNames></Trial><Trial Id="99203"><Indications><Indication>Anesthesia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Chelating agent</Action><Action>Neuromuscular blocking agent antagonist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oligosaccharide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>Germany</Country><Country>Italy</Country><Country>UK</Country><Country>Austria</Country></Countries><DateChangeLast>2019-01-31T00:00:00Z</DateChangeLast><DateEnd>2014-04-29T00:00:00Z</DateEnd><DateStart>2012-11-28T00:00:00Z</DateStart><Identifiers><Identifier>2012-001886-33</Identifier><Identifier>8616-076-00</Identifier><Identifier>8616-076-01</Identifier><Identifier>MK-8616-076</Identifier><Identifier>MK-8616-076-03</Identifier><Identifier>NCT01728584</Identifier><Identifier>P07982</Identifier><Identifier>P07982 AM1</Identifier><Identifier>SCH 900616</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Insufflation alone</Intervention><Intervention>rocuronium (Zemuron) alone</Intervention><Intervention>sugammadex alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>127</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this pilot study was to compare the use of deep or standard neuromuscular blockade (NMB) in combination with low or standard insufflation pressure in patients undergoing a surgical procedure, laparoscopic cholecystectomy. The primary hypothesis of the study was that the use of sustained deep NMB improves the surgeon's overall satisfaction with surgical conditions as compared to standard NMB.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination with Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-04-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Beate Zwerdling</Name><Name>Divisione Ricerca Clinica</Name><Name>Ingrid Kuhn</Name><Name>Karl Boegl</Name><Name>Medical Director</Name><Name>Tiffany Woo, MS</Name></ContactNames></Trial><Trial Id="99198"><Indications><Indication>Atopic dermatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Thymic stromal lymphopoietin ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Dermatological agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-005560-95</Identifier><Identifier>8226-003</Identifier><Identifier>MK-8226-003</Identifier><Identifier>MK-8226-003 AM1</Identifier><Identifier>MK-8226-003 AM2</Identifier><Identifier>NCT01732510</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MK-8226 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>This was a three-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in patients with moderate to severe atopic dermatitis. Part 1 (multiple rising dose study) objective was to find the maximum tolerated dose (MTD) of MK-8226 and to assess safety and PK. Part 2 objective was to determine safety, PK, and preliminary efficacy. Part 3 objective was to further define safety and PK, and explore MK-8226 PK/PD to model the</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dermatitis - Assessment of Clinical Response - Assessment of pruritus</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Cytokines and chemokine levels</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Dermatitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Dermatitis - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Dermatitis - Other protocol specified outcomes - Assessment of other medication use</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Eczema Area and Severity Index (EASI) score</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Scoring Atopic Dermatitis (SCORAD) Index</EndpointIndex><EndpointIndex>Pruritus - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pruritus - Assessment of Laboratory/Diagnostic Measures - Hematologic/blood chemistry assessment</EndpointIndex><EndpointIndex>Pruritus - Assessment of Therapy Related Outcomes - Assessment of treatment effectiveness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD)</PatientSegment><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD) - Subjects with moderate to severe atopic dermatitis</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with dermatitis/eczema</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 17 </BiomarkerName><BiomarkerName> C-C motif chemokine 22</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gert Andersen</Name><Name>Joyce Cox</Name><Name>Kaisa Elomaa</Name><Name>Karl Boegl</Name><Name>Mauricio Ede</Name><Name>Medical Director</Name></ContactNames></Trial><Trial Id="93121"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>South Africa</Country><Country>Ukraine</Country><Country>Lithuania</Country><Country>Portugal</Country><Country>Estonia</Country><Country>Spain</Country><Country>Germany</Country><Country>Switzerland</Country><Country>Chile</Country><Country>Greece</Country><Country>Turkey</Country><Country>Colombia</Country><Country>Brazil</Country><Country>Romania</Country><Country>Taiwan</Country><Country>Austria</Country><Country>Italy</Country><Country>Canada</Country><Country>UK</Country><Country>US</Country><Country>Argentina</Country><Country>Hungary</Country><Country>India</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2016-11-21T00:00:00Z</DateEnd><DateStart>2012-12-13T00:00:00Z</DateStart><Identifiers><Identifier>0517-029</Identifier><Identifier>2012-002340-24</Identifier><Identifier>DRKS00005372</Identifier><Identifier>MK#0517-029</Identifier><Identifier>MK-0517-029</Identifier><Identifier>NCT01697579</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ondansetron alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , fosaprepitant , ondansetron</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant , when administered with ondansetron (with or without dexamethasone), for the prevention of chemotherapy induced nausea and vomiting (CINV) in children from birth to 17 years of age  (changed to birth to &amp;lt; 12 years of age in Amendment 04). The main objective of the trial was to determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - General cancers</PatientSegment><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-11-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>25</NumberOfSites><ContactNames><Name>Alev Eren</Name><Name>Andrius Bacevicius</Name><Name>Christiane Belly</Name><Name>Clinical Trials Department</Name><Name>Divisione Ricerca Clinica</Name><Name>Eduardo Portuondo</Name><Name>Eran Gefen</Name><Name>Francesca Carvajal</Name><Name>Global Clinical Trial Operations</Name><Name>Global Clinical Trials Operations</Name><Name>Karl Boegl</Name><Name>Lai Jen</Name><Name>Maria Hernandez</Name><Name>Martina Kollmann</Name><Name>Medical Director</Name><Name>Oscar Espinoza</Name><Name>Ricardo Germano</Name><Name>Zorana Radak-Jovanovic</Name></ContactNames></Trial><Trial Id="85398"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus protease inhibitor</Action><Action>Hepatitis C virus protein NS4B inhibitor</Action><Action>Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Prodrug</Technology><Technology>Protein conjugation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company><Company>Schering Corp</Company></CompaniesSponsor><Countries><Country>Lithuania</Country><Country>Hungary</Country><Country>Poland</Country><Country>Sweden</Country><Country>Czech Republic</Country><Country>Austria</Country><Country>UK</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Belgium</Country><Country>Estonia</Country><Country>Portugal</Country><Country>Germany</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2015-05-19T00:00:00Z</DateEnd><DateStart>2012-05-30T00:00:00Z</DateStart><Identifiers><Identifier>040 [P07755]</Identifier><Identifier>12K-439</Identifier><Identifier>2011-001345-32</Identifier><Identifier>CTRI/2012/12/003200</Identifier><Identifier>DRKS00005753</Identifier><Identifier>MK-3034-040</Identifier><Identifier>MK-3034-040-00</Identifier><Identifier>MK-3034-040-01</Identifier><Identifier>MK-3034-040-02</Identifier><Identifier>MK-3034-040-07</Identifier><Identifier>MK3034-040 10697</Identifier><Identifier>NCT01544920</Identifier><Identifier>NMRR-11-1010-10697</Identifier><Identifier>P07755</Identifier><Identifier>P07755 Amnd-01 dated 08 Dec 2011</Identifier><Identifier>PHRR131022-000133</Identifier><Identifier>SCH503034</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including boceprevir , peginterferon alfa-2a , ribavirin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>737</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary purpose of this study was to compare the efficacy of two boceprevir -containing therapeutic regimens using non-inferiority in the treatment of naive patients with chronic hepatitis C virus (HCV) genotype 1 who have the IL-28B CC allele. The regimens differ in the treatment for patients who achieved HCV ribonucleic acid (RNA) undetectability at the end of the peginterferon alfa-2a plus ribavirin 4-week lead-in. The primary endpoint of this study was sustained virological response (SVR</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Rapid Virologic Response (RVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hepatitis C virus RNA </BiomarkerName><BiomarkerName> Interleukin 28B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-05-19T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>Alexander Bedenkov</Name><Name>Clinical Trials Departament</Name><Name>Clinical Trials Department</Name><Name>Dominique Blazy</Name><Name>Felipe Arbelaez</Name><Name>Francesca Carvajal</Name><Name>Global Clinical Trials Operations</Name><Name>Joyce Cox</Name><Name>Karl Boegl</Name><Name>Karl Boegl</Name><Name>Kayde Chan Kah Wei</Name><Name>Medical Director</Name><Name>Ms Hong Lih Chun</Name><Name>Nina Derkits</Name><Name>Soraya Cedraro</Name></ContactNames></Trial><Trial Id="72283"><Indications><Indication>Clostridium difficile infection</Indication><Indication>Inflammatory bowel disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Cytochrome P450 reductase inhibitor</Action><Action>Peptidoglycan recognition protein inhibitor</Action><Action>RNA polymerase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Clostridium difficile toxin B inhibitor</Action><Action>Cytochrome P450 reductase inhibitor</Action><Action>Peptidoglycan recognition protein inhibitor</Action><Action>RNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Macrolide antibiotic</Action><Action>RNA synthesis inhibitor</Action><Action>RNA synthesis modulator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antidiarrhoeal</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Bacterial pathogenicity factor modulator</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Lipopolysaccharide binding agent</Action><Action>Macrolide antibiotic</Action><Action>RNA synthesis inhibitor</Action><Action>RNA synthesis modulator</Action><Action>Synergist</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Glycoprotein</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology><Technology>Toxin binding protein</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Israel</Country><Country>Czech Republic</Country><Country>Germany</Country><Country>Denmark</Country><Country>Portugal</Country><Country>New Zealand</Country><Country>Italy</Country><Country>Puerto Rico</Country><Country>Chile</Country><Country>India</Country><Country>UK</Country><Country>US</Country><Country>Finland</Country><Country>Spain</Country><Country>Belgium</Country><Country>Canada</Country><Country>Australia</Country></Countries><DateChangeLast>2019-05-20T00:00:00Z</DateChangeLast><DateEnd>2014-12-09T00:00:00Z</DateEnd><DateStart>2011-10-10T00:00:00Z</DateStart><Identifiers><Identifier>2011-004590-90</Identifier><Identifier>3415A-001</Identifier><Identifier>MK-3415A-001</Identifier><Identifier>MODIFY I</Identifier><Identifier>NCT01241552</Identifier><Identifier>UKCRN ID: 11241</Identifier></Identifiers><IndicationsAdverse><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including fidaxomicin , metronidazole , vancomycin</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including actoxumab , bezlotoxumab , fidaxomicin , metronidazole , vancomycin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1452</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to investigate: Whether treatment with MK-3415A (actoxumab + bezlotoxumab) in addition to standard of care (SOC) antibiotic therapy would decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 (bezlotoxumab) or MK-3415 (actoxumab). Whether treatment with MK-3415A , MK-6072 , or MK-3415 , in addition to SOC antibiotic therapy would decrease CDI recurrence (rCDI) as compared to placebo. Whether MK-3415A , MK-6072 , and MK-3415 would be generally</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Clostridium difficile infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Clostridium difficile infection - Assessment of Clostridium Colonization</EndpointIndex><EndpointIndex>Clostridium difficile infection - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Clostridium difficile infection - Assessment of Gastrointestinal Symptoms</EndpointIndex><EndpointIndex>Clostridium difficile infection - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MODIFY I: A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium difficile Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Clostridium difficile infection - Subjects With Clostridium Difficile-Associated Diarrhea</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>101</NumberOfSites><ContactNames><Name>Danny Hulster</Name><Name>Director Clinical Research</Name><Name>Divisione Ricerca Clinica</Name><Name>Dr. Dale Gerding</Name><Name>Dr. Mark Wilcox</Name><Name>Francesca Carvajal</Name><Name>Gary Jankelowitz</Name><Name>Gert Andersen</Name><Name>Global Clinical Trials Operations</Name><Name>Joyce Cox</Name><Name>Karl Boegl</Name><Name>Kerin Wincott</Name><Name>Maria Hernandez</Name><Name>Mary Beth Dorr</Name><Name>Medical Director</Name><Name>Merck Sharp &amp; Dohme Corp.</Name><Name>Michel Cimon</Name><Name>Patrizia Favini</Name><Name>Susanne Zottl</Name></ContactNames></Trial><Trial Id="72822"><Indications><Indication>Varicella zoster virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>MSD Italia SRL</Company></CompaniesCollaborator><CompaniesSponsor><Company>Merck &amp; Co Inc</Company><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Turkey</Country><Country>Czech Republic</Country><Country>Puerto Rico</Country><Country>Saudi Arabia</Country><Country>Argentina</Country><Country>Canada</Country><Country>Venezuela</Country><Country>Mexico</Country><Country>Singapore</Country><Country>UK</Country><Country>Greece</Country><Country>Honduras</Country><Country>India</Country><Country>Estonia</Country><Country>Croatia</Country><Country>Jordan</Country><Country>Austria</Country><Country>Lebanon</Country><Country>North Korea</Country><Country>Panama</Country><Country>Taiwan</Country><Country>Chile</Country><Country>Philippines</Country><Country>Guatemala</Country><Country>Belgium</Country><Country>Russian Federation</Country><Country>Romania</Country><Country>United Arab Emirates</Country><Country>Italy</Country><Country>Thailand</Country><Country>Germany</Country><Country>Ecuador</Country><Country>Bulgaria</Country><Country>Lithuania</Country><Country>US</Country><Country>Australia</Country><Country>New Zealand</Country><Country>Peru</Country><Country>Hong Kong</Country><Country>Brazil</Country><Country>Spain</Country><Country>Slovakia</Country><Country>South Korea</Country><Country>Colombia</Country></Countries><DateChangeLast>2019-05-04T00:00:00Z</DateChangeLast><DateEnd>2017-04-11T00:00:00Z</DateEnd><DateStart>2011-06-24T00:00:00Z</DateStart><Identifiers><Identifier>011</Identifier><Identifier>011-00</Identifier><Identifier>011-01</Identifier><Identifier>10K-2155</Identifier><Identifier>2010-023156-89</Identifier><Identifier>CTRI/2012/05/002673</Identifier><Identifier>H-1107-117-371</Identifier><Identifier>KCT0000393</Identifier><Identifier>NCT01254630</Identifier><Identifier>PHRR131014-000130</Identifier><Identifier>V-212-011 AM2</Identifier><Identifier>V212-011</Identifier><Identifier>V212-011 AM3</Identifier><Identifier>V212-PN011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>V-212 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5305</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V-212 when administered to adults with solid tumor malignancy (STM) or hematological malignancy (HM) and to determine whether V-212 reduces the incidence of herpes zoster (HZ) in adults with STM or HM, as compared to placebo and to evaluate V-212 effect on the appearance of HZ in adults with HM. The primary hypothesis was that vaccination with V-212 would reduce the incidence of HZ compared with</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of complications - Incidence of herpes zoster complications</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Incidence/Prevalence of Herpes Infections/Diseases - Incidence/prevalence of VZV infection/disease</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of complications - Incidence of herpes zoster complications</EndpointIndex><EndpointIndex>Herpesvirus infection - Incidence/Prevalence of Herpes Infections/Diseases - Incidence/prevalence of VZV infection/disease</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Solid tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Solid tumor - Assessment of pain</EndpointIndex><EndpointIndex>Solid tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematological Malignancy</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpes Virus Vaccine - Subjects at risk of developing disease</PatientSegment><PatientSegment>Herpes Virus Vaccine - Subjects with Prior/Current Herpes Virus Infections</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Epstein-Barr Virus Infections</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections</PatientSegment><PatientSegment>Pain - Subjects with Cancer Related Pain</PatientSegment><PatientSegment>Solid tumor - Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interferon gamma</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-04-11T00:00:00Z</PrimaryCompletionDate><TrialDuration>69 Months</TrialDuration><NumberOfSites>240</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Beatrice J Tiangco</Name><Name>Beatrice Tiangco</Name><Name>Clinical Development Scientist</Name><Name>Clinical Research Director</Name><Name>Clinical Trials Operations</Name><Name>Dr Beverley Cowper</Name><Name>Eun Hee Park</Name><Name>Global Clinical Trial Operations</Name><Name>Hanna Lee</Name><Name>Karl Boegl</Name><Name>Kerin Wincott</Name><Name>Medical Director</Name><Name>Paola Chiaretta Fattore</Name><Name>Priscilla Caguioa</Name><Name>Sabine Muller (CPM)</Name><Name>Sung-Soo Yoon</Name></ContactNames></Trial><Trial Id="98699"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>TNF antagonist</Action><Action>TNF binding agent</Action><Action>Type II TNF receptor modulator</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein fusion</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company><Company>Sun Pharma Global Fze</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Czech Republic</Country><Country>Austria</Country><Country>Hungary</Country><Country>US</Country><Country>Israel</Country><Country>Netherlands</Country><Country>Denmark</Country><Country>Canada</Country><Country>Italy</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2020-12-04T00:00:00Z</DateEnd><DateStart>2013-02-05T00:00:00Z</DateStart><Identifiers><Identifier>2012-001377-88</Identifier><Identifier>3222-011</Identifier><Identifier>MK-3222-011</Identifier><Identifier>NCT01729754</Identifier><Identifier>P07771</Identifier><Identifier>reSURFACE 2</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Death</Indication><Indication>Melanoma</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>etanercept alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>tildrakizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1090</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This randomized, double-blind, placebo-controlled, multicenter, pivotal study was being conducted to evaluate the efficacy and safety/tolerability of SCH-900222/ MK-3222 or Ilumetri in a population of patients with moderate-to-severe plaque psoriasis [ 1759431 ], [ 1783419 ], [ 1905647 ], [ 1911492 ], [ 2016033 ], [ 2073723 ], [ 2073725 ], [ 2006462 ]. [ 2045121 ], [ 2006610 ], [ 2006448 ], [ 2014629 ], [ 2074843 ], [ 2124743 ]. The primary hypotheses of the study was that tildrakizumab was</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>reSURFACE 2: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH-900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for phototherapy</PatientSegment><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for systemic therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> LDL-C/HDL-C ratio </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total cholesterol/HDL-C ratio </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>94 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Caroline Doomebos</Name><Name>Danny Hulster</Name><Name>Dominique Blazy</Name><Name>Gert Andersen</Name><Name>Global Clinical Trials Operations</Name><Name>Karl Boegl</Name><Name>Kim Papp, MD</Name><Name>Medical Director</Name><Name>Patrizia Nardini</Name><Name>Shantanu Mehta</Name><Name>Simona Martinkova</Name></ContactNames></Trial><Trial Id="70628"><Indications><Indication>Ankylosing spondylitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>Russian Federation</Country><Country>Lithuania</Country><Country>Argentina</Country><Country>Taiwan</Country><Country>India</Country><Country>Estonia</Country><Country>Belgium</Country><Country>Hungary</Country><Country>Poland</Country><Country>Romania</Country><Country>Canada</Country><Country>Germany</Country><Country>UK</Country><Country>France</Country><Country>Slovakia</Country><Country>US</Country><Country>Mexico</Country><Country>South Africa</Country><Country>Austria</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateEnd>2014-11-12T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>0663-108</Identifier><Identifier>108</Identifier><Identifier>2010-019872-65</Identifier><Identifier>CTRI/2011/07/001927</Identifier><Identifier>MK-0663-108</Identifier><Identifier>MK-0663-108 AM1</Identifier><Identifier>NCT01208207</Identifier></Identifiers><InterventionsControlDisplay><Intervention>naproxen alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>etoricoxib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1015</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary objectives were to evaluate the improvement in spinal pain intensity over 6 weeks of treatment with etoricoxib 90 or 60 mg compared to naproxen; and to evaluate the improvement in spinal pain intensity over 6 weeks of treatment with etoricoxib 90 mg compared with etoricoxib 60 mg. Additionally the added benefit of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Pain - Spinal pain/Back pain (assessed by VAS)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Two-Part, 26-week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - NSAIDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Stable medication</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with back pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>67</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Alexander Bedenkov</Name><Name>Andrius Bacevicius</Name><Name>Dominique Blazy</Name><Name>Felipe Arbelaez</Name><Name>Francesca Carvajal</Name><Name>Joyce Cox</Name><Name>Karl Boegl</Name><Name>Medical Director</Name><Name>Michel Cimon</Name><Name>Steven Hildemann</Name></ContactNames></Trial><Trial Id="135654"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Hypoglycemic agent</Action><Action>Insulin release stimulator</Action><Action>Sulphonylurea antidiabetic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology><Technology>Weekly dosing</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Serbia</Country><Country>Italy</Country><Country>Slovakia</Country><Country>Austria</Country><Country>Estonia</Country><Country>Sweden</Country><Country>US</Country><Country>Ukraine</Country><Country>Germany</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Spain</Country><Country>Hungary</Country><Country>Argentina</Country><Country>Bulgaria</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-04-03T00:00:00Z</DateEnd><DateStart>2013-07-08T00:00:00Z</DateStart><Identifiers><Identifier>2013-000301-23</Identifier><Identifier>3102-027</Identifier><Identifier>MK-3102-027</Identifier><Identifier>NCT01863667</Identifier></Identifiers><InterventionsControlDisplay><Intervention>glimepiride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>omarigliptin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this trial was to assess the safety and efficacy of omarigliptin ( MK-3102 ) compared with the sulfonylurea, glimepiride , in type 2 diabetes mellitus participants who were metformin intolerant or who had a contraindication to the use of metformin. The primary hypothesis was that after 54 weeks, the mean change from baseline in hemoglobin A1c (A1C) in participants treated with omarigliptin would be non-inferior compared with that in participants treated with glimepiride.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects Inadequately Controlled with Oral Hypoglycemic Agents</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-04-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>62</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Andrius Bacevicius</Name><Name>Cesar Rodriguez</Name><Name>Danny Hulster</Name><Name>Eran Gefen</Name><Name>Eva Kaszasova</Name><Name>Global Clinical Trials Operations</Name><Name>Karl Boegl</Name><Name>Maria Koroleva</Name><Name>Medical Director</Name><Name>Patrizia Nardini</Name><Name>Simona Martinkova</Name></ContactNames></Trial><Trial Id="96402"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AMP activated protein kinase stimulator</Action><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Biguanide antidiabetic product</Action><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action><Action>Insulin release stimulator</Action><Action>Sulphonylurea antidiabetic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology><Technology>Weekly dosing</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Italy</Country><Country>Netherlands</Country><Country>Hungary</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2015-06-30T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-003626-24</Identifier><Identifier>3102-011</Identifier><Identifier>MK-3102-011</Identifier><Identifier>MK-3102-011 AM2</Identifier><Identifier>NCT01717313</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>glimepiride alone</Intervention><Intervention>metformin hydrochloride alone</Intervention><Intervention>metformin hydrochloride plus omarigliptin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>329</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the safety and efficacy and tolerability of MK-3102 (omarigliptin), dosed once-weekly on A1C in subjects with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet and exercise. The primary hypothesis was that after 24 weeks, treatment with MK-3102 compared with placebo provides greater reduction in hemoglobin A1c (A1C).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Glucose Levels - Mean plasma glucose (MPG)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Type 2 Diabetes Subjects Controlled by Diet/Exercise</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Cesar Recto</Name><Name>Danny Hulster</Name><Name>Diana Zhang</Name><Name>Eran Gefen</Name><Name>Gary Jankelowitz</Name><Name>Global Clinical Trials Operations</Name><Name>Karl Boegl</Name><Name>Kristian Lobner</Name><Name>Lai Jen</Name><Name>Medical Director</Name><Name>Nitin Mulgaonkar</Name><Name>Patrizia Nardini</Name><Name>Simona Martinkova</Name><Name>Trea Galien</Name><Name>Yong Kim</Name></ContactNames></Trial><Trial Id="71020"><Indications><Indication>Parkinsons disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>MAO B inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Adenosine A2a receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiparkinsonian</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antidepressant</Action><Action>Antiparkinsonian</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Immuno-oncology</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company><Company>Schering-Plough Research Institute</Company></CompaniesSponsor><Countries><Country>Latvia</Country><Country>Italy</Country><Country>Bulgaria</Country><Country>Netherlands</Country><Country>Portugal</Country><Country>Finland</Country><Country>Lithuania</Country><Country>Austria</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Sweden</Country><Country>Spain</Country><Country>UK</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>10650</Identifier><Identifier>2009-015162-57</Identifier><Identifier>CTRI/2012/07/002811</Identifier><Identifier>NCT01215227</Identifier><Identifier>P06153</Identifier><Identifier>P06153 AM3</Identifier><Identifier>SACT_1151</Identifier></Identifiers><InterventionsControlDisplay><Intervention>rasagiline alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>preladenant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>839</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The primary purpose of this extension study was to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 (P04938) and NCT01227265 (P07037) with moderate to severe Parkinson's Disease (PD). The study would also characterize the long-term efficacy of preladenant in participants with PD. Participants would continue to receive their stable regimen of levodopa (L-dopa) plus any adjunct medications during the study as prescribed by their physician. Several</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Clinical Symptoms - Assessment of neuropsychiatric symptoms</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Sleep - Assessment of sleep parameters</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Parkinsons disease - Clinical Assessments - Assessment of liver function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Active-Controlled Extension Study to NCT01155466 (P04938) and NCT01227265 (P07037) (P06153)</TitleDisplay><PatientSegmentTerms><PatientSegment>Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-07-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>33</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Alexander Bedenkov</Name><Name>Caroline Doorneboos</Name><Name>David J. Hewitt, MD</Name><Name>Dominique Blazy</Name><Name>Felipe Arbelaez</Name><Name>Joyce Cox</Name><Name>Kaisa Elomaa</Name><Name>Karl Boegl</Name><Name>Kenneth Wolski, MD</Name><Name>Medical Director</Name><Name>Michel Cimon</Name><Name>Patrizia Favini</Name></ContactNames></Trial><Trial Id="70619"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company><Company>PAREXEL International</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Slovakia</Country><Country>South Africa</Country><Country>Russian Federation</Country><Country>India</Country><Country>Argentina</Country><Country>Lithuania</Country><Country>Belgium</Country><Country>Romania</Country><Country>Poland</Country><Country>Canada</Country><Country>Taiwan</Country><Country>Peru</Country><Country>Finland</Country><Country>Guatemala</Country><Country>Colombia</Country><Country>UK</Country><Country>Czech Republic</Country><Country>Austria</Country><Country>Mexico</Country><Country>Germany</Country></Countries><DateChangeLast>2019-01-28T00:00:00Z</DateChangeLast><DateEnd>2014-07-29T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>0663-107</Identifier><Identifier>107-00</Identifier><Identifier>2010-019871-31</Identifier><Identifier>CTRI/2011/07/001926</Identifier><Identifier>MK-0663-107</Identifier><Identifier>MK-0663-107 AM1</Identifier><Identifier>NCT01208181</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Edema</Indication><Indication>Headache</Indication><Indication>Hypertension</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>etoricoxib (60/60 mg</Intervention><Intervention>part II) alone</Intervention><Intervention>etoricoxib (60/90 mg</Intervention><Intervention>part II) alone</Intervention><Intervention>etoricoxib (part I) alone</Intervention><Intervention>etoricoxib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1404</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a two-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis. The hypothesis was that etoricoxib (60 and 90 mg) administration would demonstrate superior efficacy compared to placebo, after 6 weeks of treatment as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in patients global assessment of pain from baseline</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by American College of Rheumatology Criteria(ACR)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response - Proportion of patients achieving ACR 20</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Remission - Patient Global Assessment of Response to Therapy</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Patient assessment of pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>91</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Alexander Bedenkov</Name><Name>Alfredo Wilkinson</Name><Name>Andrius Bacevicius</Name><Name>Anirban Roychowdhury</Name><Name>Chandra Mouli</Name><Name>Felipe Arbelaez</Name><Name>Francesca Carvajal</Name><Name>Joyce Cox</Name><Name>Jugal Kishore</Name><Name>Karl Boegl</Name><Name>Medical Director</Name><Name>Michel Cimon</Name><Name>Naresh Shetty</Name><Name>Reena Sharma</Name><Name>Sarvajeet Pal</Name><Name>Soraya Cedraro</Name><Name>Steven Hildemann</Name></ContactNames></Trial><Trial Id="94216"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology><Technology>Weekly dosing</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Finland</Country><Country>Netherlands</Country><Country>Sweden</Country><Country>Norway</Country><Country>Canada</Country><Country>Brazil</Country><Country>Taiwan</Country><Country>Turkey</Country><Country>France</Country><Country>Hungary</Country><Country>Italy</Country><Country>Czech Republic</Country><Country>Slovakia</Country><Country>Saudi Arabia</Country><Country>India</Country><Country>Belgium</Country><Country>Hong Kong</Country><Country>Mexico</Country><Country>US</Country><Country>Peru</Country><Country>Japan</Country><Country>Germany</Country><Country>Jordan</Country><Country>Austria</Country><Country>Denmark</Country><Country>Lithuania</Country><Country>Argentina</Country><Country>Poland</Country><Country>Croatia</Country><Country>Spain</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2017-03-22T00:00:00Z</DateEnd><DateStart>2012-10-05T00:00:00Z</DateStart><Identifiers><Identifier>100279</Identifier><Identifier>2012-002414-39</Identifier><Identifier>3102-018</Identifier><Identifier>DRN728</Identifier><Identifier>HKUCTR-1789</Identifier><Identifier>MK-3102-018</Identifier><Identifier>MK-3102-018 13326</Identifier><Identifier>MK-3102-018 AM5</Identifier><Identifier>NCT01703208</Identifier><Identifier>NMRR-12-858-13326</Identifier><Identifier>OMNEON</Identifier><Identifier>UKCRN 12979</Identifier><Identifier>UW 13-345</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omarigliptin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4202</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the cardiovascular (CV) safety profile of MK-3102 (omarigliptin) in subjects with type 2 diabetes mellitus (T2DM). The primary hypothesis was that the treatment with MK-3102 25 mg qw would be non-inferior to treatment with placebo and active comparators across the MK-3102 program with regard to the risk of developing a confirmed event in the primary CV composite endpoint. Main objectives of the trial are: To assess the impact of MK-3102 25 mg qw on time to</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Composite Cardiovascular Endpoints</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Safety and Tolerability - Assessment of major adverse cardiovascular events (MACE)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Stroke</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of angina</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of hospitalization - Hospitalization due to coronary artery disease (Angina/MI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Angina pectoris</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Stroke</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Time to cardiovascular event</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Composite Endpoint</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Stroke</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OMNEON: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus</TitleDisplay><PatientSegmentTerms><PatientSegment>Atherosclerosis - Subjects on Treatment for Atherosclerosis/Associated Risk Factors - Subjects on antidiabetic treatment</PatientSegment><PatientSegment>Atherosclerosis - Subjects with Peripheral Atherosclerosis</PatientSegment><PatientSegment>Atherosclerosis - Subjects with comorbid conditions - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects on other single antidiabetic agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects only on metformin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring Insulin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Type 2 Diabetes Subjects Controlled by Diet/Exercise</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - PAD Subjects with Diabetes</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-05-13T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>44</NumberOfSites><ContactNames><Name>ANUAR ZAINI BIN MD.ZAIN</Name><Name>Adam Czernik</Name><Name>Amal Chalfoun</Name><Name>Andina Hrabar</Name><Name>Andrius Bacevicius</Name><Name>Anthony Alfieri</Name><Name>CHONG JUN WOON</Name><Name>Caroline Angelucci</Name><Name>Christine Siew</Name><Name>Danny Hulster</Name><Name>Dominique Blazy</Name><Name>Eran Gefen</Name><Name>Eva Kaszasova</Name><Name>Francesca Carvajal</Name><Name>Gary Jankelowitz</Name><Name>Gert Andersen</Name><Name>Global Clinical Trials Operations</Name><Name>HKUCTR Administrator</Name><Name>Kaisa Elomaa</Name><Name>Karl Boegl</Name><Name>LAI LI RONG</Name><Name>Lai Jen</Name><Name>Lee Li Yuan</Name><Name>Maria Hernandez</Name><Name>Mauricio Ede</Name><Name>Medical Director</Name><Name>PAREXEL</Name><Name>Prof. Hung-fat Tse</Name><Name>Trea Galien</Name></ContactNames></Trial><Trial Id="59011"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Peptidomimetic</Technology><Technology>Prodrug</Technology><Technology>Protein conjugation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Merck &amp; Co Inc</Company><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Spain</Country><Country>Lithuania</Country><Country>Israel</Country><Country>Austria</Country><Country>Chile</Country><Country>North Korea</Country><Country>US</Country><Country>Germany</Country><Country>France</Country><Country>Taiwan</Country><Country>Sweden</Country><Country>Belgium</Country><Country>Canada</Country><Country>Puerto Rico</Country><Country>Thailand</Country><Country>South Korea</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Australia</Country><Country>New Zealand</Country></Countries><DateChangeLast>2019-06-21T00:00:00Z</DateChangeLast><DateEnd>2013-05-29T00:00:00Z</DateEnd><DateStart>2009-10-23T00:00:00Z</DateStart><Identifiers><Identifier>2009-013053-15</Identifier><Identifier>2009_615</Identifier><Identifier>7009-028-00</Identifier><Identifier>MK-7009-028</Identifier><Identifier>MK-7009-028 AM5</Identifier><Identifier>MK7009</Identifier><Identifier>NCT00943761</Identifier><Identifier>PN028</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including peginterferon alfa-2a , ribavirin , vaniprevir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to provide MK-7009 600 mg bid in combination with pegylated interferon ( Pegasys ) and ribavirin to patients with chronic hepatitis C virus (HCV) infection who did not achieve viral eradication while participating in a prior MK-7009 clinical trial (MK-7009-004, NCT00518622 ; MK-7009-007, NCT00704405 ; MK-7009-009, NCT00704184 ; and MK-7009-029, NCT00954993 ). Secondary objectives of the trial: In patients previously treated with placebo + peg-IFN + RBV in a MK-7009 clinical trial, evaluate</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hepatitis C virus RNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>36</NumberOfSites><ContactNames><Name>Adam Czernik</Name><Name>Andras Festa</Name><Name>Andrius Bacevicius</Name><Name>Anna Ruszczynska-Wolska</Name><Name>Avery Ince</Name><Name>Baruch Weinreb</Name><Name>Clinical Project Manager</Name><Name>Clinical Research Director</Name><Name>Danny Dhulster</Name><Name>David Woolner</Name><Name>Dominique Blazy</Name><Name>Gary Jankelowitz</Name><Name>Jean-Marie Goehrs</Name><Name>Jorge Vinces</Name><Name>Karl Boegl</Name><Name>Lai Jeng</Name><Name>Maria Hernandez</Name><Name>Medical Director</Name><Name>Michel Cimon</Name><Name>Nathalie Schrameijer</Name><Name>Paul Duffy</Name><Name>Raanan Cohen</Name><Name>Simona Martinkova</Name><Name>Steve Kim</Name><Name>Suchai Kitsiripornchai</Name><Name>Thomas Lang</Name><Name>Tryggve Ljung</Name><Name>Yong Kim</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>